Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 80/100

Failure Rate

33.3%

2 terminated/withdrawn out of 6 trials

Success Rate

60.0%

-26.5% vs industry average

Late-Stage Pipeline

17%

1 trials in Phase 3/4

Results Transparency

67%

2 of 3 completed trials have results

Key Signals

1 recruiting2 with results

Enrollment Performance

Analytics

N/A

2(40.0%)

Phase 2

2(40.0%)

Phase 3

1(20.0%)

5Total

N/A(2)

Phase 2(2)

Phase 3(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (6)

Showing 6 of 6 trials

NCT04852770Not ApplicableTerminated

Efficacy of TBCT, MBHP and PPT for PTSD During the Covid-19 Pandemics

Role: lead

NCT01854762Phase 2Terminated

Antiretroviral Regimens Containing Raltegravir for Prophylaxis of Mother-to-child-transmission of HIV Infection

Role: lead

NCT04326504Recruiting

Dolutegravir and Clinical Outcomes Among ART-recipients in Brazil

Role: lead

NCT01837277Phase 2Completed

Impact of a Dolutegravir-based Regimen on Early Mortality of AIDS Patients

Role: lead

NCT04808973Phase 3Completed

DTG Plus 3TC for Prophylaxis of Mother-to-child Transmission of HIV Infection in Pregnant Women

Role: lead

NCT03751046Not ApplicableCompleted

Cognitive Therapy in Patients Failing ART

Role: lead

All 6 trials loaded